Aldose Reductase Inhibitor for Diabetic Retinopathy Prevention

This study is about testing an enzyme-blocking drug called Sorbinil in people with diabetes. The enzyme, aldose reductase (AR), is believed to cause complications in diabetes, such as cataracts and retinopathy. By blocking AR, Sorbinil may help prevent or slow down these complications. The study is particularly interested in diabetic retinopathy, a condition that affects the eyes and can lead to blindness. This research is important as it could potentially improve care for people with diabetes and reduce the risk of vision loss. Initially, participants in the study took a daily dose of 250 mg of Sorbinil. However, due to some serious allergic reactions, the dosage was changed to a gradual increase, starting from 25 mg and reaching 250 mg after a month. The study includes regular check-ups, with weekly visits for the first month, monthly visits for the next two months, and then every three months. Additional visits are required for those on the gradual dosage increase. During these visits, various tests are conducted, including eye examinations, heart health checks, and measurements of red blood cell sorbitol levels. Participants are also asked to note any signs of allergic reactions.